These trials completed more than 12 months ago and should have reported results.

These trials are not yet due to report results: some are ongoing, some completed within the past 12 months.

These trials have problematic data on the registry. Details why »

Status Trial ID Title Completion date Category
Reported results 2013-001037-40 A phase II randomized, placebo-controlled, double-blind, dose controlled trial in patients suffering from early, newly developing abdominal or pulmonary derived septic organ dysfunction to evaluate sa... 2016-01-29 due-trials
Reported results 2015-003036-12 A phase II randomized, placebo-controlled, double-blind, dose-escalation study to evaluate safety, pharmacokinetics and pharmacodynamic dose response relationship of IFX-1 in patients undergoing compl... 2017-01-24 due-trials
Reported results 2016-002988-33 An open label Phase II trial to evaluate the safety of IFX-1 in patients with moderate to severe Hidradenitis suppurativa 2017-07-04 due-trials
Reported results 2017-004501-40 A randomized, double-blind, placebo-controlled, multicenter Phase II study to determine efficacy and safety of IFX-1 in subjects with moderate to severe hidradenitis suppurativa 2020-02-14 due-trials
Listed as ongoing, but also has a completion date and reported results 2018-000768-27 A RANDOMIZED, DOUBLE-BLIND, DOUBLE-DUMMY, ACTIVE-CONTROLLED, MULTICENTER, 2-PART PHASE II STUDY ON REPLACEMENT OF STEROIDS BY IFX-1 IN ACTIVE GRANULOMATOSIS WITH POLYANGIITIS (GPA) AND MICROSCOPIC POL... 2021-06-08 bad-data
Ongoing 2020-000864-42 OPEN LABEL, MULTICENTER PHASE II STUDY OF THE C5A-ANTIBODY IFX-1 ALONE OR IFX-1 + PEMBROLIZUMAB IN PATIENTS WITH PD-1- OR PD-L1-RESISTANT/REFRACTORY LOCALLY ADVANCED OR METASTATIC CUTANEOUS SQUAMOUS C... not-yet-due
Reported results 2020-001335-28 A pragmatic adaptive randomized controlled Phase II/III multicenter study of IFX-1 in Patients with severe COVID-19 Pneumonia - "PANAMO" 2022-01-05 due-trials
Reported results 2020-003273-21 Open label exploratory phase IIa trial to investigate the safety and efficacy of IFX-1 in treating subjects with Pyoderma Gangrenosum (OPTIMA). 2022-01-03 due-trials